BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 29, 2004
View Archived Issues
ImmunoGen, Centocor Partner In Potential $43.5M TAP Deal
ImmunoGen Inc. licensed certain rights to its Tumor-Activated Prodrug (TAP) technology to Centocor Inc. in a deal worth up to $43.5 million, plus royalties. (BioWorld Today)
Read More
ALZA Files For Approval Of Premature Ejaculation Drug
Read More
In Heart Tissue Engineering, It's Electricity, Gap, Scaffolds
Read More
Emisphere Accesses Cash Via Equity Deal, Revises Elan Debt
Read More
Other News To Note
Read More
Appointments And Advancements
Read More